Understanding GTF2H2B: A Potential Drug Target Or Biomarker (G653238)

Target Name: GTF2H2B

NCBI ID: G653238

GTF2H2B

Other Name(s): general transcription factor IIH subunit 2B (pseudogene) | General transcription factor IIH subunit 2B (pseudogene)

Understanding GTF2H2B: A Potential Drug Target Or Biomarker

General transcription factor IIH (GTF2H) is a key regulator of gene expression in many organisms, including humans. GTF2H2B is a subunit of GTF2H that has been identified as a potential drug target or biomarker. In this article, we will explore the biology of GTF2H2B and its potential as a drug target.

Background
GTF2H is a transcription factor, which means it plays a vital role in regulating gene expression. GTF2H2B is a subunit of GTF2H that contains 29 amino acids out of 31 amino acids. It has been shown to play a crucial role in the regulation of gene expression , and is often used as a drug target or biomarker.

Expression and function
GTF2H2B is a highly conserved protein that is expressed in many different tissues, including muscle, pancreas, and brain. It has been shown to play a role in the regulation of gene expression in various organisms, including humans. Studies have shown that GTF2H2B can activate or repress gene expression depending on the specific context. For example, when GTF2H2B is activated, it has been shown to promote the expression of genes involved in cell growth and differentiation, while when it is repressed, it has been shown to inhibit the expression of genes involved in cell death.

Furthermore, GTF2H2B has been shown to play a role in the regulation of cell cycle progression. It has been shown to promote the G1 phase and inhibit the S phase, which is the stage of cell growth where DNA replication occurs. This means that when GTF2H2B is activated, it promotes the growth and development of cells, while when it is repressed, it inhibits the growth and development of cells.

Potential drug target
GTF2H2B's potential as a drug target or biomarker is due to its unique structure and its role in the regulation of gene expression. One of the key reasons for its potential as a drug target is its conservation in many different organisms, which means that it is likely to be effective in humans as well. Additionally, its role in the regulation of gene expression makes it an attractive target for small molecules, which are often used as drugs.

Another potential reason for GTF2H2B's potential as a drug target is its involvement in the regulation of cancer. Studies have shown that GTF2H2B is often expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, its role in cell cycle regulation has been implicated in the development and progression of cancer.

In conclusion
GTF2H2B is a subunit of GTF2H that has been shown to play a crucial role in the regulation of gene expression. Its potential as a drug target or biomarker is due to its conservation in many different organisms and its involvement in the regulation of cell cycle progression and cancer. Further research is needed to fully understand its potential as a drug target or biomarker.

Protein Name: General Transcription Factor IIH Subunit 2B (pseudogene)

The "GTF2H2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF2H2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets